Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME, Seynaeve C, Wymenga AN, van Tinteren H, Nortier JW, Maartense E, de Graaf H, de Jongh FE, Braun JJ, Los M, Schrama JG, van Leeuwen-Stok AE, de Groot SM, Smorenburg CH. Hamaker ME, et al. Among authors: van tinteren h, van leeuwen stok ae. Breast. 2014 Feb;23(1):81-7. doi: 10.1016/j.breast.2013.11.004. Epub 2013 Dec 5. Breast. 2014. PMID: 24314824 Clinical Trial.
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Kruijtzer CMF, Verweij J, Schellens JH, Beijnen JH, Pronk L, Bo M, Lustig V, van Tinteren H, Mackay M, Ten Bokkel Huinink WW. Kruijtzer CMF, et al. Among authors: van tinteren h. Anticancer Drugs. 2000 Apr;11(4):249-55. doi: 10.1097/00001813-200004000-00004. Anticancer Drugs. 2000. PMID: 10898539 Clinical Trial.
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJ, Richelt DJ, Rodenhuis S. Schrama JG, et al. Among authors: van de vijver mj, van tinteren h. Ann Oncol. 2002 May;13(5):689-98. doi: 10.1093/annonc/mdf203. Ann Oncol. 2002. PMID: 12075736 Free article. Clinical Trial.
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.
Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG. Nieboer P, et al. Among authors: van der graaf wt, van der wall e, van tinteren h. J Clin Oncol. 2005 Nov 20;23(33):8296-304. doi: 10.1200/JCO.2005.10.167. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219926 Clinical Trial.
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Buijs C, et al. Among authors: van hoesel qg, van der wall e, van tinteren h. J Clin Oncol. 2007 Dec 1;25(34):5403-9. doi: 10.1200/JCO.2007.11.2813. J Clin Oncol. 2007. PMID: 18048822 Free article. Clinical Trial.
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. Vollebergh MA, et al. Among authors: van de vijver mj, van beers eh, van tinteren h. Ann Oncol. 2011 Jul;22(7):1561-1570. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6. Ann Oncol. 2011. PMID: 21135055 Free PMC article. Clinical Trial.
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM. Badrising S, et al. Among authors: van oort im, van den eertwegh aj, van den berg hp, van tinteren h, van der noort v. Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30. Cancer. 2014. PMID: 24382803 Free article.
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H, de Jongh FE, Braun JJ, Los M, Maartense E, van Tinteren H, Nortier JWR, Seynaeve C. Smorenburg CH, et al. Among authors: van tinteren h, van leeuwen stok ae. Ann Oncol. 2014 Mar;25(3):599-605. doi: 10.1093/annonc/mdt588. Epub 2014 Feb 6. Ann Oncol. 2014. PMID: 24504445 Free PMC article. Clinical Trial.
323 results